Download the slides from the BeOne-sponsored Satellite Symposium at European Hematology Association (EHA) 2025 to learn more about key aspects of CLL patient management, including: factors influencing individualized treatment selection; expectations for efficacy, safety, and practicality across treatment modalities; and strategies for managing infection risks.
Category: Slide-Kit
Slide kit outlining the long-term follow-up of the ASPEN trial: Zanubrutinib vs. ibrutinib in patients with Waldenström’s macroglobulinemia (WM).
Slide kit describing the results of the PFS final analysis of the ALPINE trial, a Phase 3, randomized study of zanubrutinib compared with ibrutinib in patients with relapsed/refractory (R/R) chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).
SEQUOIA is a global phase 3, open label, randomized study of zanubrutinib versus bendamustine plus rituximab (B+R) in participants with previously untreated chronic lymphocytic leukemia (CLL)



